HRHassan Rezvanian

Hassan Rezvanian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hassan Rezvanian has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Masoud Amini

    Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    9 shared publications
  • Ali Kachuei

    Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    8 shared publications
  • Ashraf Aminorroaya

    Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    8 shared publications
  • Mansour Siavash

    Medical Students’ Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran and Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    4 shared publications
  • Roya Kelishadi

    Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

    4 shared publications
  • Davood Shafie

    Heart Failure Research Center Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran

    3 shared publications

Latest Publications

  • Open Access

    Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches

    by Maryam Heidarpour, Mehrzad Mojarad, Sadegh Mazaheri-Tehrani, Ali Kachuei, Arash Najimi, Davood Shafie, Hassan Rezvanian

    Background. Metformin is commonly prescribed to treat polycystic ovary syndrome (PCOS) patients, but in some cases, it may not be effective even at high doses or may cause intolerable side effects. Therefore, recent studies have examined the impact of combining metformin with other antidiabetic medications. Methods. A systematic search was performed in Scopus, PubMed, Web of Science, and Embase up to 30 June 2023. All interventional studies that assessed the efficacy of different antidiabetic agents were included. Results. Among the 3488 records found in the primary search, 16 papers were included. Our study showed that dipeptidyl peptidase-4 inhibitors (DPP4i) had the most significant impact on glycemic profile, while thiazolidinediones (TZDs) had the most influence on lipid levels. However, it was observed that patients taking only metformin experienced a greater increase in high-density lipoprotein cholesterol (HDL-C) levels. Glucagon-like peptide-1 receptor agonists (GLP1RAs) effectively modified various anthropometric measurements, such as weight, body mass index, waist circumference, and waist-to-hip ratio. The effects of different antidiabetic drugs on hormone levels were inconclusive, although testosterone levels were more affected by GLP1RA, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and TZDs. None of the combined therapies showed a significant change in blood pressure. Conclusion. Since PCOS is a metabolic disorder, choosing the best combination of antidiabetic drugs in the clinical course of PCOS patients will be very important. Today, it seems that we need a new metabolic approach for better treatment of the metabolic aspects of these patients.


  • Open Access

    Hypophosphatemia in Coronavirus Disease 2019 (COVID‐19), Complications, and Considerations: A Systematic Review

    by Mohammad Fakhrolmobasheri, Mehrbod Vakhshoori, Maryam Heidarpour, Arash Najimi, Amir Mohamad Mozafari, Hassan Rezvanian

    Coronavirus disease 2019 (COVID-19) has various manifestations on different body organs, including the lungs, heart, kidneys, and central nervous system. However, the frequency of electrolyte abnormalities, especially hypophosphatemia, is still debated in this pandemic. Our main aim in this review is to evaluate the frequency and complications of hypophosphatemia in COVID-19-infected individuals. A systematic literature review was performed in Web of Science, Scopus, PubMed, EMBASE, and Cochrane electronic databases with the combination of different keywords till October 2021. We recruited all relevant published records (including cross-sectional and case-control studies as well as editorials and brief reports) assessing hypophosphatemia among patients with COVID-19 infection. After assessing all 928 recruited records and discarding duplicates, 4 records met the inclusion criteria. Three articles were further included during a manual search of the literature. Overall, the included studies reported 1757 subjects (males: 51.3%), with the mean age ranging from years to years. Hypophosphatemia prevalence has been reported from 7.6% to 19.5%. Patients with the severe status of COVID-19 had a higher prevalence of low serum phosphate levels than those with moderate infection. This review indicates that hypophosphatemia might be categorized as a complication in clinical settings during the COVID-19 pandemic, requiring a high clinical suspicion to implement appropriate diagnostic and therapeutic interventions to prevent life-threatening outcomes. However, it needs to be more elucidated by further studies whether hypophosphatemia in severe COVID-19 is directly related to COVID-19 or is just a complication of severe illness.


  • Open Access

    Cardiogenic Shock and Guillain–Barré Syndrome as the First Manifestations of Pheochromocytoma

    by Maryam Heidarpour, Nafiseh Sereshti, Davood Shafie, Bijan Iraj, Hassan Rezvanian

    Febrile congestive heart failure is a rare first manifestation of pheochromocytoma. Herein, the case of a 31‐year‐old female with febrile congestive heart failure and subsequent cardiogenic shock is presented. After intensive care unit (ICU) admission and further evaluating the right adrenal mass observed in abdominal ultrasonography, the diagnosis of pheochromocytoma was confirmed. Then, she was scheduled for the right adrenalectomy. Before surgery, she complained of acute‐onset progressive muscle weakness in the lower limbs, followed by the upper limbs. After further investigation, she was diagnosed with Guillain–Barré syndrome and treated with intravenous immunoglobulin (IVIG). She recovered well after the right adrenalectomy, and during the subsequent 18 months, the follow‐up did not reveal any complications, and left ventricular function recovered to normal.


  • The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis

    by Maryam Yavari, Awat Feizi, Fahimeh Haghighatdoost, Azin Ghaffari, Hassan Rezvanian

    Purpose Primary hyperparathyroidism (PHPT) is associated with increased risk of cardiovascular morbidity and mortality. We aim to determine whether parathyroidectomy (PTX) can change cardiometabolic risk factors including serum lipids, glycemic parameters, systolic and diastolic blood pressure, C reactive protein (CRP), and body mass index (BMI). Methods MEDLINE, Web of Science, Scopus, and Google Scholar were searched for relevant articles published till June 2020. Fixed-effect or random-effects models were used to estimate the weighted mean difference (WMD) and 95% CI for outcomes where applicable. Results In total, 34 studies were eligible to be included in the current meta-analysis. Our results indicated no favorable change in serum triglyceride (n = 13, WMD = −0.06, 95% CI: −0.15, 0.03 mmol/L), total cholesterol (n = 15, WMD = 0.01, 95% CI: −0.14, 0.16 mmol/L), LDL-C (n = 10, WMD = −0.01, 95% CI: −0.17, 0.19 mmol/L), HDL-C (n = 10, WMD = 0.03, 95% CI: −0.001, 0.06 mmol/L), and CRP (n = 5, WMD = 0.82, 95% CI: −0.01, 1.64 mg/L) after PTX in PHPT patients. However, glucose (n = 24, WMD = −0.16, 95% CI: −0.26, −0.06 mmol/L), serum insulin (n = 12, WMD = −1.11, 95% CI: −1.73, −0.49 µIU/mL), systolic (n = 17, WMD = −10.14, 95% CI: −12.27, −8.01 mmHg), and diastolic (n = 16, WMD = −5.21, 95% CI: −7.0, −3.43 mmHg) blood pressures were decreased after PTX, whilst a significant increase was observed in BMI (n = 13, WMD = 0.35, 95% CI: 0.19, 0.51 kg/m2). Conclusions PTX could improve glycemic parameters and blood pressure, without any significant change in serum lipoproteins and CRP.


  • Open Access

    Polyserositis: An Extremely Rare Life‐Threatening Manifestation of Pheochromocytoma

    by Maryam Heidarpour, Mohammad Ali Haghighatpanah, Hassan Rezvanian, Motahare Yadegarfar, Amir Mohammad Mozafari, Mehrbod Vakhshoori, Davood Shafie

    The pericardium is an uncommon site for manifestation of pheochromocytoma. Herein, the case of a 57‐year‐old man with cardiac tamponade is presented. Pericardiocentesis was performed, and the vital signs were stabilized afterwards. An abdominal computed tomography (CT) scan illustrated a nonhomogeneous right adrenal mass suspicious of pheochromocytoma, planned for right adrenalectomy. He recovered well after surgery, and his subsequent follow‐ups did not reveal any complications.


  • Open Access

    Acromegaly and papillary thyroid carcinoma: A case series

    by Maryam Heidarpour, Hassan Rezvanian, Ali Kachuei

    Acromegaly is a rare chronic disease and associated with an increased risk of malignancy. The issue of the risk of thyroid cancer in these patients is a topic of debate, and the number of large case–control studies is very limited. Several studies indicated that a chronic excess insulin-like growth factor-1 stimulates the proliferation of various cell types and induces an antiapoptotic effect in thyroid follicular cells. In the literature, the risk of thyroid cancer was reported greater than five-fold. In this review, we will briefly summarize the studies available regarding thyroid cancer in patients with acromegaly and present three case reports.


  • Open Access

    Assessment of the Early and Late Complication after Thyroidectomy

    by Rezvan Salehidoost, Esmaeil Chahardahmasumi, Massoud Amini, Ashraf Aminorroaya, Hassan Rezvanian, Ali Kachooei, Bijan Iraj, Masoud Nazem, Mohsen Kolahdoozan

    Background: The complications in thyroid surgery have been reported variable in literature. The aim of this study was to evaluate the early and late (3 months after surgery) complication rates of thyroidectomy in a cohort of patients undergoing thyroid surgery at two hospitals of Isfahan University of Medical Science, Iran. Materials and Methods: This study included 204 patients who candidates for thyroidectomy presenting at Medical Educational Centers of Al-Zahra and Kashani hospitals in Isfahan between March 2016 and March 2017. Clinical data are collected for all patients by continuous enrollment. The patients examined before and after thyroid surgery and the findings were recorded. Results: The highest prevalence of thyroidectomy was in women (81.9%). The most frequent thyroid surgery was total thyroidectomy and the most common indication for thyroid surgery was suspicious fine-needle aspiration for thyroid malignancy. Hypocalcemia was the most common complication with a frequency of 54.4%. The odds ratios for early complications were 2.375 and 2.542 for intermediate- and low-volume surgeons, respectively, compared to high-volume surgeons. Conclusions: According to the results of this study, the high level of surgeon's skill is effective to reduce the likelihood of late and early complications; furthermore, the chance of late complications increases with age.


  • Open Access

    The Effect of Levothyroxine and Selenium versus Levothyroxine Alone on Reducing the Level of Anti-thyroid Peroxidase Antibody in Autoimmune Hypothyroid Patients

    by Ali Kachouei, Hassan Rezvanian, Masoud Amini, Ashraf Aminorroaya, Eshagh Moradi

    Background: Due to the prevalence of autoimmune hypothyroidism and its effects on physical and mental health it is necessary to provide a treatment which is also effective in preventing the progression of sub-clinical hypothyroidism in these patients. This study aims to investigate the effect of selenium supplementation on of anti-thyroid hormone antibodies in these patients. Materials and Methods: In a randomized clinical trial, 70 patients with autoimmune hypothyroidism randomly divided into two groups of 35 each, the first group was treated with oral selenium treatment with levothyroxine (LT4) and to the second group along with LT4, placebo was also prescribed. Serum selenium level, thyroid hormones and anti-thyroid hormone antibodies before and after 3 months of treatment in both groups, were determined, and the results were analyzed using SPSS software. Results: The mean of the serum anti-thyroid peroxidase serum level in the intervention group before and after treatment was 682.18 ± 87.25 and 522.96 ± 47.21 and the difference before and after treatment was statistically significant (P = 0.021). The level of this antibody before and after treatment in the control group was 441 ± 53.54 and 501.18 ± 77.68, and no significant differences between two groups were observed before and after treatment (P = 0.42). Conclusion: Selenium supplementation may help to reduce the levels of antibodies in patients with autoimmune hypothyroidism.


  • Reduction of Insulin Resistance and Plasma Glucose Level by Salsalate Treatment in Persons With Prediabetes

    by Elham Faghihimani, Ashraf Aminorroaya, Hassan Rezvanian, Peyman Adibi, Faramarz Ismail-Beigi, Masoud Amini